Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to keep in mind that Vertex retains 60% of Casgevy profit while CRISPR ...

Scientists are using CRISPR to fast-track the domestication of a wild fruit. For roughly 10,000 years, farming communities ...

A miracle baby who was treated with a pioneering gene-therapy at CHOP has reached a major milestone as he took his first ...

A child who received the world's first personalized CRISPR therapy is now taking his first steps after months in hospital ...

CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...